Could a single antibiotic dose after sex stop STIs?
NCT ID NCT07397403
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether taking a single 200 mg dose of doxycycline within 24–72 hours after unprotected sex can prevent gonorrhea, chlamydia, and syphilis in men who have sex with men. Researchers in Bangkok will enroll 400 participants and follow them for 12 weeks. If effective, this could offer a new prevention tool for high-risk individuals.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- doxycycline
- What this could lead to
- If it works, this could provide a simple, on-demand pill to reduce the risk of common sexually transmitted infections in high-risk groups.
- What could go wrong
- This is a single-site trial in Thailand, so results may not apply elsewhere. Doxycycline may not prevent all STIs, and overuse could lead to antibiotic resistance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 days
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Biological male, aged not over 60 years Thai nationality Able to read, communicate, and understand the Thai language Men who have sex with men (MSM), aged 18 years or older and not over 60 years Having at least one of the following risk factors: A history of condomless sex, or condom failure (breakage, leakage, or slippage), via any sexual route with at least two sexual partners within the past 3 months A diagnosis of gonorrhea, chlamydia, or syphilis within the past 6 months Current use of HIV pre-exposure prophylaxis (PrEP) Willing and able to participate in study procedures (e.g., able to return to the clinic for scheduled testing for gonorrhea, chlamydia, and syphilis; able to complete doxycycline use records; and able to receive follow-up phone calls from the research team) Willing and able to provide written informed consent to participate in the study \- Exclusion Criteria: * History of allergy to tetracycline-class antibiotics Diagnosed with syphilis and not yet treated, or currently receiving treatment with benzathine penicillin G or doxycycline Receipt of benzathine penicillin G within the past 12 weeks Prior receipt of a gonorrhea vaccine Current use of medications or products that may interact with doxycycline, including: Vitamin A derivatives (e.g., isotretinoin, acitretin) Antiepileptic drugs (e.g., phenytoin, carbamazepine, phenobarbital) Immunosuppressive agents (e.g., methotrexate) Medications for heart failure or cardiac arrhythmias (e.g., digoxin) Anticoagulants (e.g., warfarin) Use of oral or injectable medications that affect blood cells, such as anticancer drugs, chemotherapy, systemic corticosteroids, or targeted therapies History of renal impairment (eGFR \< 60 mL/min/1.73 m²) or hepatic impairment (AST or ALT \> 3 times the upper limit of normal) Uncontrolled or unstable underlying diseases, such as hematologic disorders, cancer, autoimmune diseases, or neurological disorders Severe medical or psychiatric conditions that, in the investigator's judgment, may increase study-related risk or impair the participant's ability to provide informed consent Alcohol dependence (inability to control alcohol consumption, withdrawal symptoms upon reduction or cessation, or continued use despite harm) or illicit drug dependence (regular, uncontrolled use) within the past 12 months prior to enrollment, which may affect doxycycline use for STI prevention Previous participation in this study with prior randomization
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chlamydia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Bangrak STIs Center
RECRUITINGSathorn, Bangkok, 10120, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can 'Queen Mothers' bring HIV testing to the doorstep?
- A simple idea to stop STIs: send treatment home with the patient
- Pocket-sized HIV test could bring same-day diagnosis to community clinics
- New study uses DNA to track hidden gonorrhea in partners
- Can a common antibiotic prevent STIs? new study tests two dosing strategies
- One fingerstick, three infections: new rapid test under study